Beck Morgane, Michel Bruno, Rybarczyk-Vigouret Marie-Christine, Levêque Dominique, Sordet Christelle, Sibilia Jean, Velten Michel
OMEDIT Alsace, Agence Régionale de Santé Alsace Champagne-Ardenne Lorraine, 14, rue du Maréchal Juin, 67084, Strasbourg, France.
Service de Pharmacie-Stérilisation, C.H.R.U. Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
BioDrugs. 2016 Dec;30(6):585-592. doi: 10.1007/s40259-016-0202-5.
Healthcare cost savings are closely linked to prescribers' confidence in and acceptance of the prescription of biosimilar drugs.
The aim of this study was to assess the knowledge, experience and opinions of hospital-based and office-based French rheumatologists with regard to biosimilar medicines and to identify the barriers to and possible options to promote their prescription.
A web-based, self-administered survey was conducted among French rheumatologists from June 8 to August 2, 2015.
A total of 116 rheumatologists responded to the survey. Many reported having little knowledge and a lack of available information about biosimilar drugs, especially office-based rheumatologists. 98.3% of the respondents had at least one question about biosimilars, and seven in ten raised issues regarding substitution, iatrogenic effects or cost savings that might be achievable. Only eight rheumatologists had already prescribed a biosimilar drug. The most common barriers reported were indication extrapolation and a lack of data about tolerability. Nine out of ten physicians thought that starting a treatment with a biosimilar drug in biologic treatment-naïve patients was possible. The rheumatologists' opinions were rather favorable towards the implementation of biosimilars, but a majority expressed a negative opinion about substitution by the pharmacist.
Our survey gave a better appreciation of the concerns associated with biosimilar prescriptions. Targeted communication initiatives, deeper experience and availability of new clinical data may help to address the outstanding questions and should overcome the misunderstandings surrounding biosimilar drugs among rheumatologists.
医疗成本的节约与开处方者对生物类似药处方的信心及接受程度密切相关。
本研究旨在评估法国医院和诊所的风湿病专家关于生物类似药的知识、经验和观点，并确定推广其处方的障碍及可能的选择。
2015年6月8日至8月2日，对法国风湿病专家开展了一项基于网络的自填式调查。
共有116名风湿病专家回复了调查。许多人表示对生物类似药了解甚少且缺乏相关信息，尤其是诊所的风湿病专家。98.3%的受访者至少有一个关于生物类似药的问题，十分之七的人提出了关于替代、医源性效应或可能实现的成本节约等问题。只有8名风湿病专家曾开过生物类似药。报告的最常见障碍是适应症外推和缺乏耐受性数据。十分之九的医生认为在未接受过生物治疗的患者中开始使用生物类似药进行治疗是可行的。风湿病专家对生物类似药的实施普遍持赞成态度，但大多数人对药剂师进行替代持否定意见。
我们的调查更好地了解了与生物类似药处方相关的问题。有针对性的沟通举措、更深入的经验以及新临床数据的可得性可能有助于解决悬而未决的问题，并应能消除风湿病专家对生物类似药的误解。
